296 Results
Sort By:
Published on September 13, 2023
The American Association for Cancer Research (AACR) released its annual Cancer Progress Report on Wednesday that highlighted advances in cancer treatments and survival while also advocating for continued funding by the US government to sustain progress. “The advances in cancer research, particularly in the last two decades, have been breathtaking,”…
Published on September 12, 2023
Moderna and Immatics are collaborating to “pioneer novel and transformative therapies for cancer patients with high unmet medical needs,” in a deal worth potentially $1.7B+. They will combine Immatics’ T cell receptor (TCR) platform with Moderna’s mRNA technology, and span modalities including bispecifics, cell therapy, and cancer vaccines. Cambridge-based Moderna…
Published on September 6, 2023
New evidence suggests lymph nodes play a key role in why tumors that have spread to the brain respond to immunotherapy, while glioblastoma, which originates in the brain, does not. “Typically, antigen presenting cells (e.g., conventional dendritic cells, cDCs) are recruited to the tumor, where they phagocytose dead or dying tumor…
Published on August 23, 2023
Etcembly, a U.K. biotech, has developed a new immunotherapy to target hard-to-treat cancers using generative artificial intelligence (AI) similar to that used to create ChatGPT. According to the company, this is the first time a candidate immunotherapy has been designed by generative AI. The new therapeutic candidate is a bispecific…
Published on August 21, 2023
Moderna will partner with Chinese biotech CARsgen to co-develop a combined CAR T-cell and mRNA cancer vaccine therapy. The collaboration aims to combine Moderna’s Claudin18.2 mRNA cancer vaccine with CARsgen’s investigational Claudin18.2 autologous CAR T-cell product candidate (CT041) to test efficacy for targeting hard to treat cancers. Claudin 18.2 is…
Published on August 17, 2023
A multisite study published today in the Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR) shows that a commonly prescribed anxiety drug is linked with worse outcomes in pancreatic cancer patients and shorter progression-free survival (PFS). The drug, benzodiazepine lorazepam, sold under the trade name…
Published on August 9, 2023
When people talk about cancer immunotherapy, they are usually referring to immune checkpoint inhibitors, a class of drugs that is now widely used in the treatment of solid tumors. Oncolytic viruses, while under the immunotherapy umbrella, are far less well-known, even though the concept of using a virus to destroy…
Published on August 9, 2023
Immunotherapy is proving a massive draw for investors and big pharma companies alike. These privately-owned immuno-oncology startups have bagged hefty funding rounds in the last two years. For decades, the mainstays of cancer treatment have been chemotherapy, radiotherapy, and surgery. In the last decade, however, a new option has emerged:…
Published on August 9, 2023
Three therapeutic regulatory approvals in less than a year signal that the promise of the human microbiome may finally be paying off. All of the approved therapies focus on treating recurrent Clostridium difficile infection, but what is next for the field? With promising oncology-related trial results from a number of…
Published on August 4, 2023
Research led by the American Cancer Society shows that among cancer survivors, Black and Hispanic individuals who have a second primary cancer have poorer survival than their White counterparts in the U.S. In a study including more than 200,000 people, Black and Hispanic patients were 21% and 10% more likely…
Published on July 20, 2023
GDF-15’s role in resistance to cancer immunotherapy was reinforced in a Nature Communications study published today. The researchers demonstrated that GDF-15 blocks LFA-1-dependent T cell recruitment into the tumor microenvironment, a prerequisite for responses to anti-PD-1/-L1 treatment and other immunotherapeutic strategies. This, the authors say, is the first paper to…
Published on July 13, 2023
The genetic drivers of papillary craniopharyngiomas, a rare brain tumor, were targeted by a combination treatment that led to a 91 percent response rate in a new trial. The trial was led by investigators from the Mass General Cancer Center and the first multicenter treatment protocol for this type of…
Published on July 5, 2023
Researchers at the Massachusetts Institute of Technology (MIT) say they have used a vaccine that boosts CAR T therapy and it may be a method that can help this form of immunotherapy effectively treat solid tumors. The MIT researchers have found a way to overcome one of the obstacles to…
Published on June 22, 2023
A team of researchers lead by the Harvard Medical School has developed a new cancer diagnosis tool that merges structural details with molecular information about tumors allowing pathologists to identify biological markers of the disease, potentially improving cancer diagnosis and treatment. For centuries, one of the most prevalent and trustworthy…
Published on June 7, 2023
Results from a Phase II clinical trial show immunotherapy with pembrolizumab provided a benefit in 42 percent of patients with brain cancer that metastasized from a range of primary tumors. This study was designed as an open-label, single-stage, single-arm Phase II clinical trial evaluating the intracranial efficacy of pembrolizumab, a…